Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- PMID: 37591583
- PMCID: PMC10447222
- DOI: 10.1016/S2214-109X(23)00305-4
Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
Abstract
Background: The epidemiology of human papillomavirus (HPV) in women has been well documented. Less is known about the epidemiology of HPV in men. We aim to provide updated global and regional pooled overall, type-specific, and age-specific prevalence estimates of genital HPV infection in men.
Methods: We conducted a systematic review and meta-analysis to assess the prevalence of genital HPV infection in the general male population. We searched Embase, Ovid MEDLINE, and the Global Index Medicus for studies published between Jan 1, 1995, and June 1, 2022. Inclusion criteria were population-based surveys in men aged 15 years or older or HPV prevalence studies with a sample size of at least 50 men with no HPV-related pathology or known risk factors for HPV infection that collected samples from anogenital sites and used PCR or hybrid capture 2 techniques for HPV DNA detection. Exclusion criteria were studies conducted among populations at increased risk of HPV infection, exclusively conducted among circumcised men, and based on urine or semen samples. We screened identified reports and extracted summary-level data from those that were eligible. Data were extracted by two researchers independently and reviewed by a third, and discrepancies were resolved by consensus. We extracted only data on mucosal α-genus HPVs. Global and regional age-specific prevalences for any HPV, high-risk (HR)-HPV, and individual HPV types were estimated using random-effects models for meta-analysis and grouped by UN Sustainable Development Goals geographical classification.
Findings: We identified 5685 publications from database searches, of which 65 studies (comprising 44 769 men) were included from 35 countries. The global pooled prevalence was 31% (95% CI 27-35) for any HPV and 21% (18-24) for HR-HPV. HPV-16 was the most prevalent HPV genotype (5%, 95% CI 4-7) followed by HPV-6 (4%, 3-5). HPV prevalence was high in young adults, reaching a maximum between the ages of 25 years and 29 years, and stabilised or slightly decreased thereafter. Pooled prevalence estimates were similar for the UN Sustainable Development Goal geographical regions of Europe and Northern America, Sub-Saharan Africa, Latin America and the Caribbean, and Australia and New Zealand (Oceania). The estimates for Eastern and South-Eastern Asia were half that of the other regions.
Interpretation: Almost one in three men worldwide are infected with at least one genital HPV type and around one in five men are infected with one or more HR-HPV types. Our findings show that HPV prevalence is high in men over the age of 15 years and support that sexually active men, regardless of age, are an important reservoir of HPV genital infection. These estimates emphasise the importance of incorporating men in comprehensive HPV prevention strategies to reduce HPV-related morbidity and mortality in men and ultimately achieve elimination of cervical cancer and other HPV-related diseases.
Funding: Instituto de Salud Carlos III, European Regional Development Fund, Secretariat for Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and Horizon 2020.
Translations: For the Spanish and French translations of the abstract see Supplementary Materials section.
© 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved. This is an Open Access article published under the CC BY NC ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
Conflict of interest statement
Declaration of interests The Cancer Epidemiology Research Program (with which LB, LA, and GA are affiliated) has received sponsorship for grants from Merck and HPV test kits at no cost from Roche for research purposes. ARG reports payments from Merck to her institution, and as consulting fees to herself, and payments from Merck for participation on an advisory board. All other authors declare no competing interests.
Figures



Comment in
-
Randomised recruitment in estimating genital human papillomavirus prevalence.Lancet Glob Health. 2024 Jan;12(1):e30. doi: 10.1016/S2214-109X(23)00517-X. Lancet Glob Health. 2024. PMID: 38097291 No abstract available.
Similar articles
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
-
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3. Cochrane Database Syst Rev. 2018. PMID: 29740819 Free PMC article.
-
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Cochrane Database Syst Rev. 2008. PMID: 18646068
-
Prevalence of human papillomaviruses in semen: a systematic review and meta-analysis.Hum Reprod. 2014 Apr;29(4):640-51. doi: 10.1093/humrep/det453. Epub 2013 Dec 22. Hum Reprod. 2014. PMID: 24365799
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
Cited by
-
Practices of French General Practitioners Regarding Vaccination of Boys Against Human Papillomavirus (HPV), One Year After the Application of Its Official Recommendation.J Cancer Educ. 2024 Jun;39(3):271-278. doi: 10.1007/s13187-024-02407-y. Epub 2024 Feb 14. J Cancer Educ. 2024. PMID: 38351431 Free PMC article.
-
Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy.Front Oncol. 2023 Dec 18;13:1273516. doi: 10.3389/fonc.2023.1273516. eCollection 2023. Front Oncol. 2023. PMID: 38179168 Free PMC article. Review.
-
Evaluation of HPV infection and presence of licensed HPV vaccine genotypes among genital warts in Foshan, China.Front Microbiol. 2024 Apr 17;15:1376141. doi: 10.3389/fmicb.2024.1376141. eCollection 2024. Front Microbiol. 2024. PMID: 38699478 Free PMC article.
-
Breaking barriers: why including boys and men is key to HPV prevention.BMC Med. 2024 Nov 8;22(1):525. doi: 10.1186/s12916-024-03701-8. BMC Med. 2024. PMID: 39516809 Free PMC article.
-
Overcoming Barriers to Human Papillomavirus Vaccination in Guangdong Province, China.Vaccines (Basel). 2025 Apr 29;13(5):482. doi: 10.3390/vaccines13050482. Vaccines (Basel). 2025. PMID: 40432094 Free PMC article. Review.
References
-
- Bouvard V, Baan R, Straif K, et al. A review of human carcinogens—part B: biological agents. Lancet Oncol. 2009;10:321–322. - PubMed
-
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
-
- de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e180–e190. - PubMed